Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders

Fibroblast growth factor (FGF) 21 is a member of the endocrine FGF subfamily. FGF21 expression is induced under different disease conditions, such as type 2 diabetes, obesity, chronic kidney diseases, and cardiovascular diseases, and it has a broad spectrum of functions in regulating various metabol...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jun, Li, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633491/
https://www.ncbi.nlm.nih.gov/pubmed/26594197
http://dx.doi.org/10.3389/fendo.2015.00168
_version_ 1782399207145996288
author Zhang, Jun
Li, Yang
author_facet Zhang, Jun
Li, Yang
author_sort Zhang, Jun
collection PubMed
description Fibroblast growth factor (FGF) 21 is a member of the endocrine FGF subfamily. FGF21 expression is induced under different disease conditions, such as type 2 diabetes, obesity, chronic kidney diseases, and cardiovascular diseases, and it has a broad spectrum of functions in regulating various metabolic parameters. Many different approaches have been pursued targeting FGF21 and its receptors to develop therapeutics for treating type 2 diabetes and other aspects of metabolic conditions. In this article, we summarize some of these key approaches and highlight the potential challenges in the development of these agents.
format Online
Article
Text
id pubmed-4633491
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-46334912015-11-20 Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders Zhang, Jun Li, Yang Front Endocrinol (Lausanne) Endocrinology Fibroblast growth factor (FGF) 21 is a member of the endocrine FGF subfamily. FGF21 expression is induced under different disease conditions, such as type 2 diabetes, obesity, chronic kidney diseases, and cardiovascular diseases, and it has a broad spectrum of functions in regulating various metabolic parameters. Many different approaches have been pursued targeting FGF21 and its receptors to develop therapeutics for treating type 2 diabetes and other aspects of metabolic conditions. In this article, we summarize some of these key approaches and highlight the potential challenges in the development of these agents. Frontiers Media S.A. 2015-11-05 /pmc/articles/PMC4633491/ /pubmed/26594197 http://dx.doi.org/10.3389/fendo.2015.00168 Text en Copyright © 2015 Zhang and Li. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Zhang, Jun
Li, Yang
Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders
title Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders
title_full Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders
title_fullStr Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders
title_full_unstemmed Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders
title_short Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders
title_sort fibroblast growth factor 21 analogs for treating metabolic disorders
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633491/
https://www.ncbi.nlm.nih.gov/pubmed/26594197
http://dx.doi.org/10.3389/fendo.2015.00168
work_keys_str_mv AT zhangjun fibroblastgrowthfactor21analogsfortreatingmetabolicdisorders
AT liyang fibroblastgrowthfactor21analogsfortreatingmetabolicdisorders

Ejemplares similares